Your browser doesn't support javascript.
A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic.
Triggle, Chris R; Bansal, Devendra; Ding, Hong; Islam, Md Mazharul; Farag, Elmoubashar Abu Baker Abd; Hadi, Hamad Abdel; Sultan, Ali A.
  • Triggle CR; Department of Pharmacology, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, Doha, Qatar.
  • Bansal D; Department of Health Protection & Communicable Diseases Control, Ministry of Public Health, Doha, Qatar.
  • Ding H; Department of Pharmacology, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, Doha, Qatar.
  • Islam MM; Department of Animal Resources, Ministry of Municipality and Environment, Doha, Qatar.
  • Farag EABA; Department of Health Protection & Communicable Diseases Control, Ministry of Public Health, Doha, Qatar.
  • Hadi HA; Communicable Diseases Centre, Hamad Medical Corporations, Doha, Qatar.
  • Sultan AA; Department of Microbiology and Immunology, Weill Cornell Medicine, Cornell University, Doha, Qatar.
Front Immunol ; 12: 631139, 2021.
Article in English | MEDLINE | ID: covidwho-1133911
ABSTRACT
COVID-19 emerged from China in December 2019 and during 2020 spread to every continent including Antarctica. The coronavirus, SARS-CoV-2, has been identified as the causative pathogen, and its spread has stretched the capacities of healthcare systems and negatively affected the global economy. This review provides an update on the virus, including the genome, the risks associated with the emergence of variants, mode of transmission, immune response, COVID-19 in children and the elderly, and advances made to contain, prevent and manage the disease. Although our knowledge of the mechanics of virus transmission and the immune response has been substantially demystified, concerns over reinfection, susceptibility of the elderly and whether asymptomatic children promote transmission remain unanswered. There are also uncertainties about the pathophysiology of COVID-19 and why there are variations in clinical presentations and why some patients suffer from long lasting symptoms-"the long haulers." To date, there are no significantly effective curative drugs for COVID-19, especially after failure of hydroxychloroquine trials to produce positive results. The RNA polymerase inhibitor, remdesivir, facilitates recovery of severely infected cases but, unlike the anti-inflammatory drug, dexamethasone, does not reduce mortality. However, vaccine development witnessed substantial progress with several being approved in countries around the globe.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Dexamethasone / Adenosine Monophosphate / Alanine / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Anti-Inflammatory Agents Type of study: Observational study / Prognostic study Topics: Long Covid / Vaccines / Variants Limits: Aged / Child / Humans Language: English Journal: Front Immunol Year: 2021 Document Type: Article Affiliation country: Fimmu.2021.631139

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Dexamethasone / Adenosine Monophosphate / Alanine / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Anti-Inflammatory Agents Type of study: Observational study / Prognostic study Topics: Long Covid / Vaccines / Variants Limits: Aged / Child / Humans Language: English Journal: Front Immunol Year: 2021 Document Type: Article Affiliation country: Fimmu.2021.631139